NICE
NICE recommends Bayer’s Eylea for myopic chorodial neovascularisation
September 22, 2017Medical Communications, Sales and Marketing Bayer, Eylea, NICE, pharma, pharmaceutical
Bayer has revealed that UK drug regulator NICE has given its final recommendation on blockbuster eye drug Eylea (aflibercept solution …
BMS’ Opdivo to finally be made available to lung cancer patients in the UK
September 20, 2017Research and Development, Sales and Marketing Bristol-Myers Squibb, NICE, biotech, drugs, opdivo, pharma, pharmaceutical
It is two and a half years since patients with lung cancer in the US were able to receive Bristol-Myers …
Pfizer’s leukaemia drug gets opposing regulatory decisions on either side of the Atlantic
August 18, 2017Medical Communications, Sales and Marketing Besponsa, Cancer, FDA, NICE, Pfizer, leukaemia, pharma, pharmaceutical
Pfizer has received a bittersweet bout of news as it emerges that its drug Besponsa (inotuzumab ozogamicin) has received approval …
NICE knocks back advanced kidney cancer drug duo
August 14, 2017Sales and Marketing Cancer, Kidney cancer, NICE, medicine, pharma, pharmaceutical
NICE has dished out a double judgement turning down two drugs for advanced renal cell carcinoma, a form of kidney …
Top Ten most popular articles on Pharmafile.com this week
August 11, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Merck, NICE, Parkinson's, biotech, diabetes, pharma, pharmaceutical, top ten
Another week, another busy week in pharma. The last seven days have seen some remarkable strides in the diabetes space, …
Bayer’s liver cancer drug availability spreads to UK with NICE approval
August 10, 2017Sales and Marketing Bayer, Cancer, NICE, Nexavar, life sciences, liver cancer, pharma, pharmaceutical
NICE has announced that it has given final appraisal recommending Bayer’s Nexavar (sorafenib) for the treatment of advanced hepatocellular carcinoma …
Merck scores expanded NICE recommendation in head, neck and oral cancer
August 8, 2017Manufacturing and Production, Sales and Marketing Erbitux, Merck, NICE, biotech, cetuximah, drugs, life sciences, pharma, pharmaceuticals
Merck has announced its approval of NICE’s decision to expand its recommendation of Erbitux (cetuximab) to include its use as …
NICE greenlights Celgene pancreatic cancer drug as first-line combination treatment
August 4, 2017Medical Communications, Sales and Marketing Cancer, Celgene, NICE, Pancreatic cancer, drugs, healthcare, life sciences, medicine, pharma, pharmaceuticals
Celgene is celebrating following NICE’s announcement that it had decided to recommend the use of nab-Paclitaxel, when used in combination …
Roche antibody becomes first of its kind authorised for blood cancer
July 26, 2017Research and Development, Sales and Marketing CDF, Cancer, NICE, drugs, lymphoma, pharma, pharmaceutical Roche
NICE has announced its decision to make Roche’s Gazyvaro available via the Cancer Drugs Fund (CDF) in combination with chemotherapy …
Ipsen secures NICE approval for multi-targeting kidney cancer therapy
July 11, 2017Manufacturing and Production, Sales and Marketing Cabometyx, Kidney cancer, NICE
Ipsen has announced that its therapy Cabometyx (cabozantinib) has been given approval by NICE for the treatment of advanced renal …
ABPI launches legal action to overturn £20m price cap
July 11, 2017Manufacturing and Production, Medical Communications, Sales and Marketing ABPI, NHS England, NICE
When NICE announced in March that it would impose a £20 million per year cap on the price of drugs, …
NICE agrees approval deal for ultra-rare juvenile bone disease
July 5, 2017Research and Development, Sales and Marketing Alexion, NICE, Strensiq
NICE has announced that it has decided to approve Alexion Pharma’s Strensiq (asfotase alfa) for the treatment of ultra-rare disease …
Ministers move to clarify drug regulation Post-Brexit
July 4, 2017Manufacturing and Production, Medical Communications EMA, Jeremy Hunt, MHRA, NHS, NICE
Jeremy Hunt, Health Secretary, and Greg Clark, Business Secretary, have made a bold move to suggest that the UK will …
NICE recommends AstraZeneca lung treatment
July 3, 2017Sales and Marketing AstraZeneca, Daxas, NICE
AstraZeneca’s Daxas (roflumilast) has received recommendation from NICE for the treatment of chronic obstructive pulmonary disease (COPD) it has emerged, …
Eli Lilly arthritis drug outperforms Humira and receives NICE backing
June 30, 2017Medical Communications, Research and Development, Sales and Marketing Eli Lilly, NICE, Olumiant, rheumatoid arthritis
Eli Lilly’s rheumatoid arthritis (RA) drug Olumiant (baricitinib) has been deemed cost-effective by NICE and has been recommended to be …
Latest content
FibroFind appoints Lee Borthwick as CEO
